表紙
市場調查報告書
商品編碼
1040404

心臟瓣膜症治療的全球市場(2021年∼2027年)

Valvular Heart Diseases Treatment Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球心臟瓣膜症治療的市場規模,在預測期間內預計以約8.0%的年複合成長率成長。

推動該市場成長的主要原因,是心臟瓣膜症的盛行率增加,心臟瓣膜症治療的研究開發的活躍,政府的配合措施,心臟疾病增加等。

本報告提供全球心臟瓣膜症治療市場調查,市場概要,市場成長要素及阻礙因素分析,各疾病、診斷、治療、終端用戶、地區的分析,競爭情形,再加上主要企業的簡介等全面性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的見解與目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場明細

  • 全球心臟瓣膜症治療市場:各疾病
    • 主動脈閥置換術
    • 心臟瓣膜症
    • 二尖瓣狹窄症
    • 其他(三尖瓣障礙)
  • 全球心臟瓣膜症治療市場:各診斷
    • 心導管
    • 心電圖(ECG)
    • 胸部X光
    • 壓力測試
    • 其他
  • 全球心臟瓣膜症治療市場:各治療
    • 投藥
    • 手術
  • 全球心臟瓣膜症治療市場:各終端用戶
    • 醫院&診所
    • 門診病人手術中心
    • 研究機關

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Co.
  • Biotronik SE & Co. KG
  • Boston Scientific Corp.
  • Braile Biomedica
  • Cardiac Dimensions Pty. Ltd.
  • CardiaMed
  • Cardiosolutions, Inc.
  • Cook Group Inc.
  • CryoLife, Inc.
  • Edwards Lifesciences Corp.
  • HLT, Inc.
  • JenaValve Technology, Inc.
  • Lepu Medical Technology(Beijing)Co., Ltd.
  • LivaNova PLC
  • Medtronic, PLC
  • Micro Interventional Devices, Inc.
  • NeoChord, Inc.
  • Neovasc Inc.
  • ON-X Life Technologies Inc.
  • Osypka Medical GmbH
  • Siemens Healthcare Medical Solutions Ltd.
  • Terumo Corp.
  • Toray Industries, Inc.
  • TTK Healthcare Ltd.
  • Venus Medtech
目錄
Product Code: OMR2023955

Title:
Global Valvular Heart Diseases
Market Size, Share &Trends Analysis By Diseases (Aortic Valve Replacement, Heart Valve Disease, Mitral Valve Stenosis, and Others), By Diagnosis (Cardiac Catheterization, Electrocardiogram (ECG), Chest X-Ray, Stress Testing, Others), By Treatment (Medication and Surgery), By End-Users (Hospital &Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast, 2021-2027.

The valvular heart disease treatment market is anticipated to grow at a considerable CAGR of around 8.0% during the forecast period. The key factors that impel the growth of the market include, increasing prevalence of heart valve diseases. the surge in R&D to develop enduring, and effective treatment opportunities for valvular heart disease treatment. The government initiatives act as a prospect for market growth. The growing geriatric population diagnosed with valvar heart disease, and the increased cases of cardiac disease across the globe are set to impel the market growth. Also, regulatory endorsements for new and progressive prosthetic heart valves, boost the growth of the valvular heart disease treatment market. Additionally, the approval of minimally invasive surgeries, development in the standard of healthcare facilities globally, act as an opportunity in the valvular heart disease treatment market during the forecast period. Besides, the lack of skilled surgeons acts as a challenging factor in the market growth. However, strict regulatory policies may hinder the growth of the valvular heart disease treatment market.

The valvular heart disease treatment is not facing any negative impact due to the COVID-19 pandemic. COVID-19 can be more severe to patients with prior chronic diseases. The key market players in this market are introducing new products which will help people indicated for both aortic regurgitation and stenosis. Hence, is specify that this market is not hit or faced any losses due to COVID-19 Pandemic.

The global valvular heart disease treatment market is segmented based on diseases, diagnosis, and end-user. based on disease type, the valvular heart disease treatment market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, others (tricuspid valve disorders). based on the diagnosis, the valvular heart disease treatment market is segmented into cardiac catheterization, electrocardiogram (ECG), chest x-ray, stress testing, others. based on treatment, the valvular heart disease treatment market is segmented into medication, surgery. based on end-user, the market is classified into hospitals &clinics, ambulatory surgical centers, research institutes.

The valvular heart disease treatment market is evaluated based on the geographical regions that are contributing considerably growth towards the growth of the market. Based on the geography, North America was the highest contributor of the market share due to the government initiatives, and increasing awareness about heart diseases. According to the Centres for Disease Control and Prevention (CDC), about 610,000 people in America decease due to heart diseases. The increase of heart attacks in North America would upsurge the demand for cardiovascular drugs. However, the Asia-Pacific region is projected to have the fastest growth rate during the forecast period due to the increasing geriatric population diagnosed with heart diseases in the region, and government initiatives in R&D boost the market growth in the region

Research Methodology

The market study of the global valvular heart diseases treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market
  • Whitepapers, research papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Valvular Heart Diseases Treatment Market Research and Analysis by Disease
  • Global Valvular Heart Diseases Treatment Market Research and Analysis by Diagnosis
  • Global Valvular Heart Diseases Treatment Market Research and Analysis by Treatment
  • Global Valvular Heart Diseases Treatment Market Research and Analysis by End-User

The Report Covers

  • Comprehensive research methodology of the global valvular heart diseases treatment market
  • This report also includes a detailed and extensive market overview with key analyst insights
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
  • Analysis of regional regulations and other government policies impacting the global valvular heart diseases treatment market
  • Insights about market determinants that are stimulating the global valvular heart diseases treatment market
  • Detailed and extensive market segments with the regional distribution of forecasted revenues
  • Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Valvular Heart Diseases Industry
  • Recovery Scenario of Global Valvular Heart Diseases Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Valvular Heart Diseases Market by Diseases
    • 5.1.1. Aortic Valve Replacement
    • 5.1.2. Heart Valve Disease
    • 5.1.3. Mitral Valve Stenosis
    • 5.1.4. Others (Tricuspid Valve Disorders)
  • 5.2. Global Valvular Heart Diseases Market by Diagnosis
    • 5.2.1. Cardiac Catheterization
    • 5.2.2. Electrocardiogram (ECG)
    • 5.2.3. Chest X-Ray
    • 5.2.4. Stress Testing
    • 5.2.5. Others
  • 5.3. Global Valvular Heart Diseases Market by Treatment
    • 5.3.1. Medication
    • 5.3.2. Surgery
      • 5.3.2.1. Valve Repair
      • 5.3.2.2. Valve Replacement
  • 5.4. Global VALVULAR HEART DISEASES Market by End-Users
    • 5.4.1. Hospital & Clinics
    • 5.4.2. Ambulatory Surgical Centers
    • 5.4.3. Research Institutes

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. B. Braun Melsungen AG
  • 7.3. Becton, Dickinson and Co.
  • 7.4. Biotronik SE & Co. KG
  • 7.5. Boston Scientific Corp.
  • 7.6. Braile Biomedica
  • 7.7. Cardiac Dimensions Pty. Ltd.
  • 7.8. CardiaMed
  • 7.9. Cardiosolutions, Inc.
  • 7.10. Cook Group Inc.
  • 7.11. CryoLife, Inc.
  • 7.12. Edwards Lifesciences Corp.
  • 7.13. HLT, Inc.
  • 7.14. JenaValve Technology, Inc.
  • 7.15. Lepu Medical Technology (Beijing) Co., Ltd.
  • 7.16. LivaNova PLC
  • 7.17. Medtronic, PLC
  • 7.18. Micro Interventional Devices, Inc.
  • 7.19. NeoChord, Inc.
  • 7.20. Neovasc Inc.
  • 7.21. ON-X Life Technologies Inc.
  • 7.22. Osypka Medical GmbH
  • 7.23. Siemens Healthcare Medical Solutions Ltd.
  • 7.24. Terumo Corp.
  • 7.25. Toray Industries, Inc.
  • 7.26. TTK Healthcare Ltd.
  • 7.27. Venus Medtech

LIST OF TABLES

  • 1. GLOBAL VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL VALVULAR HEART DISEASES MARKET BY DISEASES, 2020-2027 ($ MILLION)
  • 3. GLOBAL AORTIC VALVE REPLACEMENT MARKET BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL HEART VALVE DISEASE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL MITRAL VALVE STENOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL OTHER HEART VALVE DISEASE MARKET BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL VALVULAR HEART DISEASES MARKET BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 8. GLOBAL CARDIAC CATHETERIZATIONFOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL ELECTROCARDIOGRAM (ECG)FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL CHEST X-RAYFOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL STRESS TESTINGFOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL OTHERSVALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL VALVULAR HEART DISEASES MARKET BY TREATMENT, 2020-2027 ($ MILLION)
  • 14. GLOBAL MEDICATION VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBAL SURGERY FOR VALVULAR HEART DISEASES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL VALVULAR HEART DISEASES MARKET BY END-USER, 2020-2027 ($ MILLION)
  • 17. GLOBALVALVULAR HEART DISEASES FOR HOSPITAL & CLINICS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBALVALVULAR HEART DISEASES FOR AMBULATORY SURGICAL CENTERS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBALVALVULAR HEART DISEASES FOR RESEARCH INSTITUTES MARKET BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 21. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
  • 22. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 26. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
  • 27. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 28. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 29. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 30. EUROPEAN VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 31. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
  • 32. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 36. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE, 2020-2027 ($ MILLION)
  • 37. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD VALVULAR HEART DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL VALVULAR HEART DISEASES MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL VALVULAR HEART DISEASES MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL VALVULAR HEART DISEASES MARKET, 2021-2027 (%)
  • 4. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY DISEASES, 2020 VS 2027 (%)
  • 5. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 6. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 7. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 8. GLOBAL VALVULAR HEART DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL AORTIC VALVE REPLACEMENT MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL HEART VALVE DISEASE MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL MITRAL VALVE STENOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL OTHER VALVULAR HEART DISEASES MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL CARDIAC CATHETERIZATION FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL ELECTROCARDIOGRAM (ECG) FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL CHEST X-RAY FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL STRESS TESTING FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL OTHER FOR VALVULAR HEART DISEASES DIAGNOSIS MARKET BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL MEDICATION FOR VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL SURGERY FOR VALVULAR HEART DISEASES TREATMENT MARKET BY REGION, 2020 VS 2027 (%)
  • 20. GLOBAL VALVULAR HEART DISEASES FOR HOSPITAL & CLINICS MARKET BY REGION, 2020 VS 2027 (%)
  • 21. GLOBAL VALVULAR HEART DISEASES FOR AMBULATORY SURGICAL CENTERS MARKET BY REGION, 2020 VS 2027 (%)
  • 22. GLOBAL VALVULAR HEART DISEASES FOR RESEARCH INSTITUTES MARKET BY REGION, 2020 VS 2027 (%)
  • 23. US VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. CANADA MARKET VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. UK VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. GERMANY VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. SPAIN VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. FRANCE VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. ITALY VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. REST OF EUROPE VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. INDIA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. CHINA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. JAPAN VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SOUTH KOREA VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. REST OF WORLD VALVULAR HEART DISEASES MARKET SIZE, 2020-2027 ($ MILLION)